GoAI
Get started
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

TYRA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$26.05

+$0.36 · +1.40%

Aug 21, 4:00 PM ET

TYRA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

39

Expensive

Momentum

65

Gaining

Sentiment

70

Bullish

Risk resilience

52

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Todd Harris
Listed since
Sep 15, 2021
Employees
87

Market position

Day range

Current $26.05

52-week range

Current $26.05

Open
$26.27
Previous close
$25.69
Volume
493.6K
0.59× average
Average volume
832.86K
Average daily volume
Market cap
1.55B USD
Beta
0.77
Market reference 1
50-day average
$29.6299
-12.08% below average
200-day average
$29.7689
-12.49% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.5B USD
EV / EBITDA
-12.52×
Earnings yield
-7.65%
Free cash flow yield
-6.08%

Profitability & efficiency

Return on equity
-46.28%
Return on assets
-42.44%
Return on invested capital
-50.10%

Financial health

Current ratio
14.67×
Altman Z-score
29.53
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−132.76M USD-27.44%

Net income

−119.95M USD-38.70%
Income trends across reported periods−15.64M USD−58.23M USD−100.82M USD−143.41M USDOperating income, FY2021: −26.29M USDOperating income, FY2022: −58.93M USDOperating income, FY2023: −79.95M USDOperating income, FY2024: −104.18M USDOperating income, FY2025: −132.76M USDNet income, FY2021: −26.29M USDNet income, FY2022: −55.33M USDNet income, FY2023: −69.13M USDNet income, FY2024: −86.48M USDNet income, FY2025: −119.95M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −26.29M USD. Operating income FY2022 −58.93M USD. Operating income FY2023 −79.95M USD. Operating income FY2024 −104.18M USD. Operating income FY2025 −132.76M USD. Net income FY2021 −26.29M USD. Net income FY2022 −55.33M USD. Net income FY2023 −69.13M USD. Net income FY2024 −86.48M USD. Net income FY2025 −119.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development102.93M USD80.08M USD62.52M USD43.01M USD20.64M USD
Selling, general, and administrative29.83M USD24.1M USD17.43M USD15.92M USD5.65M USD
Operating expenses132.76M USD104.18M USD79.95M USD58.93M USD26.29M USD
Interest income12.82M USD17.7M USD10.81M USD3.65M USD13K USD
Depreciation and amortization546K USD519K USD357K USD296K USD140K USD
Operating income−132.76M USD−104.18M USD−79.95M USD−58.93M USD−26.29M USD
Net income−119.95M USD−86.48M USD−69.13M USD−55.33M USD−26.29M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$48.00

84.26% upside
Past 12 months12-month forecastHigh $54.00Average $48.00Low $42.00

Rating distribution

7 ratings
Strong buy00%
Buy7100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

6 institutions
JefferiesmaintainBuy

TYRA news

TYRA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TYRA

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
37.55M
Weight
0.33%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
36.2M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
24.09M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
10.89M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
8.72M
Weight
0.06%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
8.5M
Weight
0.08%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
6.58M
Weight
0.04%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
3.63M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research TYRA

research.disclaimer